+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endocrine And Metabolic Disorders Drugs Market Research Reports

From
From
From
human insulin market - Forecasts from 2025 to 2030 - Product Thumbnail Image

human insulin market - Forecasts from 2025 to 2030

  • Report
  • December 2024
  • 144 Pages
  • Global
From
From
From
Androgen Receptor Antagonists - Pipeline Insight, 2025 - Product Thumbnail Image

Androgen Receptor Antagonists - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Sodium-glucose Transporter 2 Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Sodium-glucose Transporter 2 Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Graves' Orbitopathy- Pipeline Insight, 2025 - Product Thumbnail Image

Graves' Orbitopathy- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Fabry Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Fabry Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 50 Pages
  • Global
From
Diabetic Neuropathic Pain- Pipeline Insight, 2025 - Product Thumbnail Image

Diabetic Neuropathic Pain- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Diabetic Nephropathy- Pipeline Insight, 2025 - Product Thumbnail Image

Diabetic Nephropathy- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Diabetic Foot Ulcers - Pipeline Insight, 2025 - Product Thumbnail Image

Diabetic Foot Ulcers - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Glucagon-Like Peptide 1 Receptor Agonists - Pipeline Insight, 2025 - Product Thumbnail Image

Glucagon-Like Peptide 1 Receptor Agonists - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 100 Pages
  • Global
From
Enhancer Of Zeste Homolog 2 Protein Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Enhancer Of Zeste Homolog 2 Protein Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
ANGPTL3 Protein Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

ANGPTL3 Protein Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Viral Core Protein Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Viral Core Protein Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
From
Type 1 Diabetes - Pipeline Insight, 2025 - Product Thumbnail Image

Type 1 Diabetes - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 240 Pages
  • Global
From
AL Amyloidosis- Pipeline Insight, 2025 - Product Thumbnail Image

AL Amyloidosis- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Loading Indicator

The Endocrine and Metabolic Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat endocrine and metabolic disorders. Endocrine disorders are conditions that affect the body's hormones, while metabolic disorders are conditions that affect the body's ability to process and use energy. Endocrine and metabolic disorders can include diabetes, thyroid disorders, obesity, and adrenal disorders. Endocrine and Metabolic Disorders Drugs are typically developed by pharmaceutical companies and are prescribed by physicians. These drugs can be used to treat a variety of endocrine and metabolic disorders, including diabetes, thyroid disorders, obesity, and adrenal disorders. Common drugs used to treat these conditions include insulin, metformin, and glucagon-like peptide-1 (GLP-1) agonists. Some of the major companies in the Endocrine and Metabolic Disorders Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the development, production, and marketing of drugs used to treat endocrine and metabolic disorders. Show Less Read more